Edema and Related Medical Conditions

Comprehensive information on edema, swelling, treatment and medical conditions that can cause edema. For all articles, please click on "Archives"

Saturday, November 03, 2007

Bevacizumab improved vision, macular edema in study of RVO patients

Bevacizumab improved vision, macular edema in study of RVO patients

OSN SuperSite Breaking News 10/24/2007

Bevacizumab improved visual acuity and central macular edema symptoms in patients with retinal vein occlusion within 9 weeks after treatment, according to a prospective study by researchers in Germany.

Andreas Stahl, MD, and colleagues at University of Freiburg evaluated the 9-week responses to a single injection of Avastin (bevacizumab, Genentech) in 14 central retinal vein occlusion (RVO) patients and seven branch RVO patients.

At follow-up, the researchers found that mean visual acuity for the 21 patients had increased an average of 2.4 lines (P < .01) over baseline. Also, the improvement in visual acuity was in concert with a decrease in central retinal thickness, according to the study.

The best improvement in visual acuity was reached between 3 and 6 weeks post-injection and began to decrease from 6 to 9 weeks, the authors noted.

"This [visual acuity] decrease was precipitated by an increase in [central macular edema] between week 3 and 6," they said.

In subgroup analyses, patients who received a bevacizumab injection within the first 3 months of RVO showed an average four-line gain in vision, compared with an average gain of 1.8 lines in patients treated between 4 and 6 months after RVO and a gain of 2.5 lines for those treated later than 6 months after RVO onset, according to the study.

"We did not observe any short-term adverse effects during our study," the authors noted.

The study is published in the October issue of Graefe's Archive for Clinical and Experimental Ophthalmology.

Labels: , , ,